Nantahala Capital Management LLC Acquires Shares of 600,000 Upstream Bio, Inc. (NASDAQ:UPB)

Nantahala Capital Management LLC purchased a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 600,000 shares of the company’s stock, valued at approximately $9,864,000. Nantahala Capital Management LLC owned approximately 1.12% of Upstream Bio at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Moody Aldrich Partners LLC bought a new stake in shares of Upstream Bio during the fourth quarter valued at approximately $1,229,000. Corebridge Financial Inc. acquired a new stake in Upstream Bio in the fourth quarter worth about $142,000. Bain Capital Life Sciences Investors LLC acquired a new position in Upstream Bio during the 4th quarter valued at about $37,735,000. Bank of New York Mellon Corp bought a new stake in Upstream Bio during the fourth quarter worth approximately $607,000. Finally, Geode Capital Management LLC acquired a new position in Upstream Bio during the fourth quarter worth about $5,973,000.

Upstream Bio Price Performance

UPB stock opened at $8.39 on Monday. Upstream Bio, Inc. has a 12 month low of $5.14 and a 12 month high of $29.46. The firm has a 50 day simple moving average of $7.87 and a 200 day simple moving average of $14.45.

Upstream Bio Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.